Haptoglobin Genotype as a Determinant of Benefit or Harm From Niacin for Participants With Diabetes.

One hypothesis that may explain the apparent failure of recent trials of high-density lipoprotein (HDL)-raising therapy is based on the finding that HDL may become proatherogenic under certain circumstances [(1,2)][1], with the proposed result that raising HDL levels in these individuals would be